nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimipramine—ABCB1—esophageal cancer	0.571	1	CbGaD
Trimipramine—HTR3A—vagus nerve—esophageal cancer	0.015	0.298	CbGeAlD
Trimipramine—HTR2A—vagus nerve—esophageal cancer	0.00607	0.12	CbGeAlD
Trimipramine—Paresthesia of limbs—Methotrexate—esophageal cancer	0.0056	0.0538	CcSEcCtD
Trimipramine—Inappropriate antidiuretic hormone secretion—Cisplatin—esophageal cancer	0.00337	0.0324	CcSEcCtD
Trimipramine—Ileus paralytic—Capecitabine—esophageal cancer	0.00333	0.032	CcSEcCtD
Trimipramine—Bone marrow depression—Capecitabine—esophageal cancer	0.00214	0.0205	CcSEcCtD
Trimipramine—Throat sore—Capecitabine—esophageal cancer	0.002	0.0192	CcSEcCtD
Trimipramine—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.00198	0.0191	CcSEcCtD
Trimipramine—Body temperature increased—Carboplatin—esophageal cancer	0.00188	0.0181	CcSEcCtD
Trimipramine—Tingling sensation—Capecitabine—esophageal cancer	0.00179	0.0172	CcSEcCtD
Trimipramine—Petechiae—Capecitabine—esophageal cancer	0.00175	0.0168	CcSEcCtD
Trimipramine—HTR3A—digestive system—esophageal cancer	0.00171	0.0338	CbGeAlD
Trimipramine—Bone marrow depression—Methotrexate—esophageal cancer	0.00159	0.0153	CcSEcCtD
Trimipramine—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00159	0.0152	CcSEcCtD
Trimipramine—Coordination abnormal—Capecitabine—esophageal cancer	0.00147	0.0141	CcSEcCtD
Trimipramine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00145	0.0139	CcSEcCtD
Trimipramine—HTR3A—lung—esophageal cancer	0.00143	0.0283	CbGeAlD
Trimipramine—ADRA1A—epithelium—esophageal cancer	0.0014	0.0278	CbGeAlD
Trimipramine—HTR2A—neck—esophageal cancer	0.00133	0.0264	CbGeAlD
Trimipramine—Petechiae—Methotrexate—esophageal cancer	0.0013	0.0125	CcSEcCtD
Trimipramine—SLC6A4—digestive system—esophageal cancer	0.0013	0.0258	CbGeAlD
Trimipramine—SLC6A3—lung—esophageal cancer	0.00119	0.0235	CbGeAlD
Trimipramine—Vascular purpura—Capecitabine—esophageal cancer	0.00117	0.0112	CcSEcCtD
Trimipramine—Pancytopenia—Cisplatin—esophageal cancer	0.00117	0.0112	CcSEcCtD
Trimipramine—Libido decreased—Capecitabine—esophageal cancer	0.00113	0.0108	CcSEcCtD
Trimipramine—SLC6A4—lung—esophageal cancer	0.00109	0.0215	CbGeAlD
Trimipramine—Purpura—Capecitabine—esophageal cancer	0.00109	0.0104	CcSEcCtD
Trimipramine—HRH1—epithelium—esophageal cancer	0.00108	0.0215	CbGeAlD
Trimipramine—CYP2C19—digestive system—esophageal cancer	0.00108	0.0214	CbGeAlD
Trimipramine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00108	0.0104	CcSEcCtD
Trimipramine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00107	0.0103	CcSEcCtD
Trimipramine—Myocardial infarction—Cisplatin—esophageal cancer	0.00107	0.0103	CcSEcCtD
Trimipramine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00107	0.0103	CcSEcCtD
Trimipramine—Stomatitis—Cisplatin—esophageal cancer	0.00107	0.0103	CcSEcCtD
Trimipramine—ADRA2A—bronchus—esophageal cancer	0.00105	0.0208	CbGeAlD
Trimipramine—HRH1—smooth muscle tissue—esophageal cancer	0.00104	0.0207	CbGeAlD
Trimipramine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00104	0.00998	CcSEcCtD
Trimipramine—Urinary retention—Capecitabine—esophageal cancer	0.000995	0.00957	CcSEcCtD
Trimipramine—Ataxia—Capecitabine—esophageal cancer	0.000984	0.00946	CcSEcCtD
Trimipramine—Gynaecomastia—Methotrexate—esophageal cancer	0.00096	0.00923	CcSEcCtD
Trimipramine—HRH1—trachea—esophageal cancer	0.000959	0.019	CbGeAlD
Trimipramine—SLC6A2—lung—esophageal cancer	0.000957	0.019	CbGeAlD
Trimipramine—ADRA2A—trachea—esophageal cancer	0.000942	0.0187	CbGeAlD
Trimipramine—Tinnitus—Cisplatin—esophageal cancer	0.000916	0.0088	CcSEcCtD
Trimipramine—Flushing—Cisplatin—esophageal cancer	0.000912	0.00876	CcSEcCtD
Trimipramine—HTR2A—epithelium—esophageal cancer	0.000906	0.0179	CbGeAlD
Trimipramine—Arrhythmia—Cisplatin—esophageal cancer	0.000877	0.00843	CcSEcCtD
Trimipramine—HTR2A—smooth muscle tissue—esophageal cancer	0.000873	0.0173	CbGeAlD
Trimipramine—DRD2—lung—esophageal cancer	0.000872	0.0173	CbGeAlD
Trimipramine—Alopecia—Cisplatin—esophageal cancer	0.000868	0.00834	CcSEcCtD
Trimipramine—Pancytopenia—Capecitabine—esophageal cancer	0.000859	0.00826	CcSEcCtD
Trimipramine—CYP2C9—digestive system—esophageal cancer	0.000836	0.0166	CbGeAlD
Trimipramine—Carbamazepine—ABCC2—esophageal cancer	0.000827	0.153	CrCbGaD
Trimipramine—HRH1—digestive system—esophageal cancer	0.000825	0.0163	CbGeAlD
Trimipramine—Weight increased—Capecitabine—esophageal cancer	0.000823	0.00791	CcSEcCtD
Trimipramine—Vision blurred—Cisplatin—esophageal cancer	0.000806	0.00775	CcSEcCtD
Trimipramine—Tremor—Cisplatin—esophageal cancer	0.000801	0.0077	CcSEcCtD
Trimipramine—HTR2A—trachea—esophageal cancer	0.000801	0.0159	CbGeAlD
Trimipramine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000795	0.00764	CcSEcCtD
Trimipramine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000795	0.00764	CcSEcCtD
Trimipramine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000793	0.00763	CcSEcCtD
Trimipramine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000791	0.0076	CcSEcCtD
Trimipramine—Myocardial infarction—Capecitabine—esophageal cancer	0.000791	0.0076	CcSEcCtD
Trimipramine—Stomatitis—Capecitabine—esophageal cancer	0.000786	0.00756	CcSEcCtD
Trimipramine—Jaundice—Capecitabine—esophageal cancer	0.000786	0.00756	CcSEcCtD
Trimipramine—Malaise—Cisplatin—esophageal cancer	0.000771	0.00741	CcSEcCtD
Trimipramine—Agranulocytosis—Capecitabine—esophageal cancer	0.000753	0.00723	CcSEcCtD
Trimipramine—Convulsion—Cisplatin—esophageal cancer	0.000741	0.00712	CcSEcCtD
Trimipramine—Ataxia—Methotrexate—esophageal cancer	0.000733	0.00704	CcSEcCtD
Trimipramine—Anxiety—Cisplatin—esophageal cancer	0.000725	0.00697	CcSEcCtD
Trimipramine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00072	0.00692	CcSEcCtD
Trimipramine—Discomfort—Cisplatin—esophageal cancer	0.000719	0.00691	CcSEcCtD
Trimipramine—Oedema—Cisplatin—esophageal cancer	0.000698	0.00671	CcSEcCtD
Trimipramine—HTR2A—digestive system—esophageal cancer	0.000689	0.0137	CbGeAlD
Trimipramine—HRH1—lung—esophageal cancer	0.000689	0.0137	CbGeAlD
Trimipramine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000683	0.00657	CcSEcCtD
Trimipramine—Tachycardia—Cisplatin—esophageal cancer	0.000681	0.00655	CcSEcCtD
Trimipramine—ADRA2A—lung—esophageal cancer	0.000677	0.0134	CbGeAlD
Trimipramine—Tinnitus—Capecitabine—esophageal cancer	0.000675	0.00649	CcSEcCtD
Trimipramine—Flushing—Capecitabine—esophageal cancer	0.000672	0.00646	CcSEcCtD
Trimipramine—Eosinophilia—Methotrexate—esophageal cancer	0.000667	0.00641	CcSEcCtD
Trimipramine—Anorexia—Cisplatin—esophageal cancer	0.000665	0.00639	CcSEcCtD
Trimipramine—SLC6A2—lymph node—esophageal cancer	0.000655	0.013	CbGeAlD
Trimipramine—Hypotension—Cisplatin—esophageal cancer	0.000652	0.00627	CcSEcCtD
Trimipramine—Arrhythmia—Capecitabine—esophageal cancer	0.000647	0.00622	CcSEcCtD
Trimipramine—Alopecia—Capecitabine—esophageal cancer	0.00064	0.00615	CcSEcCtD
Trimipramine—Pancytopenia—Methotrexate—esophageal cancer	0.00064	0.00615	CcSEcCtD
Trimipramine—CYP3A4—digestive system—esophageal cancer	0.000638	0.0126	CbGeAlD
Trimipramine—CYP2D6—digestive system—esophageal cancer	0.000628	0.0124	CbGeAlD
Trimipramine—Paraesthesia—Cisplatin—esophageal cancer	0.000627	0.00602	CcSEcCtD
Trimipramine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00062	0.00596	CcSEcCtD
Trimipramine—Dysgeusia—Capecitabine—esophageal cancer	0.000617	0.00593	CcSEcCtD
Trimipramine—Decreased appetite—Cisplatin—esophageal cancer	0.000607	0.00583	CcSEcCtD
Trimipramine—Drowsiness—Methotrexate—esophageal cancer	0.0006	0.00577	CcSEcCtD
Trimipramine—Vision blurred—Capecitabine—esophageal cancer	0.000594	0.00571	CcSEcCtD
Trimipramine—ABCB1—epithelium—esophageal cancer	0.000593	0.0118	CbGeAlD
Trimipramine—Tremor—Capecitabine—esophageal cancer	0.000591	0.00568	CcSEcCtD
Trimipramine—Stomatitis—Methotrexate—esophageal cancer	0.000585	0.00563	CcSEcCtD
Trimipramine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000585	0.00562	CcSEcCtD
Trimipramine—HTR2A—lung—esophageal cancer	0.000575	0.0114	CbGeAlD
Trimipramine—Feeling abnormal—Cisplatin—esophageal cancer	0.000575	0.00553	CcSEcCtD
Trimipramine—Methadone—CYP19A1—esophageal cancer	0.000572	0.106	CrCbGaD
Trimipramine—Malaise—Capecitabine—esophageal cancer	0.000568	0.00546	CcSEcCtD
Trimipramine—Agranulocytosis—Methotrexate—esophageal cancer	0.00056	0.00539	CcSEcCtD
Trimipramine—Palpitations—Capecitabine—esophageal cancer	0.000557	0.00535	CcSEcCtD
Trimipramine—Desipramine—CYP2A6—esophageal cancer	0.000554	0.103	CrCbGaD
Trimipramine—Body temperature increased—Cisplatin—esophageal cancer	0.000552	0.0053	CcSEcCtD
Trimipramine—Hypertension—Capecitabine—esophageal cancer	0.000544	0.00523	CcSEcCtD
Trimipramine—Anxiety—Capecitabine—esophageal cancer	0.000535	0.00514	CcSEcCtD
Trimipramine—Discomfort—Capecitabine—esophageal cancer	0.00053	0.0051	CcSEcCtD
Trimipramine—Dry mouth—Capecitabine—esophageal cancer	0.000525	0.00504	CcSEcCtD
Trimipramine—ABCB1—trachea—esophageal cancer	0.000525	0.0104	CbGeAlD
Trimipramine—Confusional state—Capecitabine—esophageal cancer	0.000519	0.00499	CcSEcCtD
Trimipramine—Nortriptyline—PTGS1—esophageal cancer	0.000516	0.0955	CrCbGaD
Trimipramine—Oedema—Capecitabine—esophageal cancer	0.000514	0.00494	CcSEcCtD
Trimipramine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000504	0.00484	CcSEcCtD
Trimipramine—Tinnitus—Methotrexate—esophageal cancer	0.000503	0.00483	CcSEcCtD
Trimipramine—Tachycardia—Capecitabine—esophageal cancer	0.000502	0.00483	CcSEcCtD
Trimipramine—Asthenia—Cisplatin—esophageal cancer	0.000501	0.00481	CcSEcCtD
Trimipramine—Anorexia—Capecitabine—esophageal cancer	0.00049	0.00471	CcSEcCtD
Trimipramine—Epinastine—ABCB1—esophageal cancer	0.000485	0.0898	CrCbGaD
Trimipramine—Hypotension—Capecitabine—esophageal cancer	0.000481	0.00462	CcSEcCtD
Trimipramine—Diarrhoea—Cisplatin—esophageal cancer	0.000477	0.00459	CcSEcCtD
Trimipramine—Diphenhydramine—PTGS1—esophageal cancer	0.000477	0.0883	CrCbGaD
Trimipramine—Alopecia—Methotrexate—esophageal cancer	0.000476	0.00458	CcSEcCtD
Trimipramine—HRH1—lymph node—esophageal cancer	0.000471	0.00934	CbGeAlD
Trimipramine—Insomnia—Capecitabine—esophageal cancer	0.000465	0.00447	CcSEcCtD
Trimipramine—ADRA2A—lymph node—esophageal cancer	0.000463	0.00917	CbGeAlD
Trimipramine—Paraesthesia—Capecitabine—esophageal cancer	0.000462	0.00444	CcSEcCtD
Trimipramine—Dysgeusia—Methotrexate—esophageal cancer	0.000459	0.00442	CcSEcCtD
Trimipramine—Dyspepsia—Capecitabine—esophageal cancer	0.000453	0.00435	CcSEcCtD
Trimipramine—ABCB1—digestive system—esophageal cancer	0.000451	0.00895	CbGeAlD
Trimipramine—Decreased appetite—Capecitabine—esophageal cancer	0.000447	0.0043	CcSEcCtD
Trimipramine—Vomiting—Cisplatin—esophageal cancer	0.000444	0.00426	CcSEcCtD
Trimipramine—Fatigue—Capecitabine—esophageal cancer	0.000444	0.00426	CcSEcCtD
Trimipramine—Vision blurred—Methotrexate—esophageal cancer	0.000442	0.00425	CcSEcCtD
Trimipramine—Rash—Cisplatin—esophageal cancer	0.00044	0.00423	CcSEcCtD
Trimipramine—Constipation—Capecitabine—esophageal cancer	0.00044	0.00423	CcSEcCtD
Trimipramine—Dermatitis—Cisplatin—esophageal cancer	0.00044	0.00423	CcSEcCtD
Trimipramine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000435	0.00418	CcSEcCtD
Trimipramine—Feeling abnormal—Capecitabine—esophageal cancer	0.000424	0.00407	CcSEcCtD
Trimipramine—Malaise—Methotrexate—esophageal cancer	0.000423	0.00407	CcSEcCtD
Trimipramine—Nausea—Cisplatin—esophageal cancer	0.000415	0.00398	CcSEcCtD
Trimipramine—Urticaria—Capecitabine—esophageal cancer	0.000409	0.00393	CcSEcCtD
Trimipramine—Abdominal pain—Capecitabine—esophageal cancer	0.000407	0.00391	CcSEcCtD
Trimipramine—Body temperature increased—Capecitabine—esophageal cancer	0.000407	0.00391	CcSEcCtD
Trimipramine—Convulsion—Methotrexate—esophageal cancer	0.000407	0.00391	CcSEcCtD
Trimipramine—Discomfort—Methotrexate—esophageal cancer	0.000395	0.00379	CcSEcCtD
Trimipramine—Confusional state—Methotrexate—esophageal cancer	0.000386	0.00371	CcSEcCtD
Trimipramine—ABCB1—lung—esophageal cancer	0.000377	0.00747	CbGeAlD
Trimipramine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000375	0.0036	CcSEcCtD
Trimipramine—Asthenia—Capecitabine—esophageal cancer	0.000369	0.00355	CcSEcCtD
Trimipramine—Anorexia—Methotrexate—esophageal cancer	0.000365	0.00351	CcSEcCtD
Trimipramine—Pruritus—Capecitabine—esophageal cancer	0.000364	0.0035	CcSEcCtD
Trimipramine—Hypotension—Methotrexate—esophageal cancer	0.000358	0.00344	CcSEcCtD
Trimipramine—Diarrhoea—Capecitabine—esophageal cancer	0.000352	0.00338	CcSEcCtD
Trimipramine—Insomnia—Methotrexate—esophageal cancer	0.000346	0.00333	CcSEcCtD
Trimipramine—Paraesthesia—Methotrexate—esophageal cancer	0.000344	0.00331	CcSEcCtD
Trimipramine—Somnolence—Methotrexate—esophageal cancer	0.00034	0.00327	CcSEcCtD
Trimipramine—Dizziness—Capecitabine—esophageal cancer	0.00034	0.00327	CcSEcCtD
Trimipramine—Dyspepsia—Methotrexate—esophageal cancer	0.000337	0.00324	CcSEcCtD
Trimipramine—Decreased appetite—Methotrexate—esophageal cancer	0.000333	0.0032	CcSEcCtD
Trimipramine—Fatigue—Methotrexate—esophageal cancer	0.00033	0.00317	CcSEcCtD
Trimipramine—Vomiting—Capecitabine—esophageal cancer	0.000327	0.00314	CcSEcCtD
Trimipramine—Rash—Capecitabine—esophageal cancer	0.000324	0.00312	CcSEcCtD
Trimipramine—Dermatitis—Capecitabine—esophageal cancer	0.000324	0.00311	CcSEcCtD
Trimipramine—Headache—Capecitabine—esophageal cancer	0.000322	0.0031	CcSEcCtD
Trimipramine—Feeling abnormal—Methotrexate—esophageal cancer	0.000316	0.00303	CcSEcCtD
Trimipramine—Nausea—Capecitabine—esophageal cancer	0.000306	0.00294	CcSEcCtD
Trimipramine—Carbamazepine—ABCB1—esophageal cancer	0.000304	0.0564	CrCbGaD
Trimipramine—Urticaria—Methotrexate—esophageal cancer	0.000304	0.00292	CcSEcCtD
Trimipramine—Body temperature increased—Methotrexate—esophageal cancer	0.000303	0.00291	CcSEcCtD
Trimipramine—Abdominal pain—Methotrexate—esophageal cancer	0.000303	0.00291	CcSEcCtD
Trimipramine—Asthenia—Methotrexate—esophageal cancer	0.000275	0.00264	CcSEcCtD
Trimipramine—Pruritus—Methotrexate—esophageal cancer	0.000271	0.0026	CcSEcCtD
Trimipramine—Diarrhoea—Methotrexate—esophageal cancer	0.000262	0.00252	CcSEcCtD
Trimipramine—ABCB1—lymph node—esophageal cancer	0.000258	0.00511	CbGeAlD
Trimipramine—Clomipramine—ABCB1—esophageal cancer	0.000256	0.0475	CrCbGaD
Trimipramine—Dizziness—Methotrexate—esophageal cancer	0.000253	0.00243	CcSEcCtD
Trimipramine—Vomiting—Methotrexate—esophageal cancer	0.000243	0.00234	CcSEcCtD
Trimipramine—Rash—Methotrexate—esophageal cancer	0.000241	0.00232	CcSEcCtD
Trimipramine—Dermatitis—Methotrexate—esophageal cancer	0.000241	0.00232	CcSEcCtD
Trimipramine—Headache—Methotrexate—esophageal cancer	0.00024	0.00231	CcSEcCtD
Trimipramine—Nausea—Methotrexate—esophageal cancer	0.000227	0.00219	CcSEcCtD
Trimipramine—Promethazine—ABCB1—esophageal cancer	0.000227	0.0421	CrCbGaD
Trimipramine—Doxepin—ABCB1—esophageal cancer	0.000225	0.0417	CrCbGaD
Trimipramine—Methadone—ABCB1—esophageal cancer	0.000224	0.0414	CrCbGaD
Trimipramine—Desipramine—ABCB1—esophageal cancer	0.000206	0.0382	CrCbGaD
Trimipramine—Chlorpromazine—ABCB1—esophageal cancer	0.000176	0.0326	CrCbGaD
Trimipramine—Imipramine—ABCB1—esophageal cancer	0.000175	0.0324	CrCbGaD
Trimipramine—Amitriptyline—ABCB1—esophageal cancer	0.000174	0.0322	CrCbGaD
Trimipramine—ABCB1—Metabolism—PSME1—esophageal cancer	2.85e-05	0.000106	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—TGFBR2—esophageal cancer	2.84e-05	0.000106	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.84e-05	0.000106	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.83e-05	0.000105	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—TGFBR2—esophageal cancer	2.83e-05	0.000105	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—CREBBP—esophageal cancer	2.79e-05	0.000104	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—TGFBR2—esophageal cancer	2.78e-05	0.000103	CbGpPWpGaD
Trimipramine—HTR1D—Signaling by GPCR—EGFR—esophageal cancer	2.74e-05	0.000102	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—SMAD4—esophageal cancer	2.73e-05	0.000102	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—ENO1—esophageal cancer	2.72e-05	0.000101	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PTGS1—esophageal cancer	2.72e-05	0.000101	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—TYMP—esophageal cancer	2.71e-05	0.000101	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PTGS1—esophageal cancer	2.7e-05	0.0001	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—ENO1—esophageal cancer	2.7e-05	0.0001	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—SMAD4—esophageal cancer	2.69e-05	0.0001	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—SMAD4—esophageal cancer	2.68e-05	9.98e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PSME2—esophageal cancer	2.68e-05	9.98e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PSME1—esophageal cancer	2.68e-05	9.98e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PSME2—esophageal cancer	2.66e-05	9.89e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PSME1—esophageal cancer	2.66e-05	9.89e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—HIF1A—esophageal cancer	2.64e-05	9.81e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	2.63e-05	9.8e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	2.63e-05	9.8e-05	CbGpPWpGaD
Trimipramine—HTR1D—GPCR downstream signaling—PIK3CA—esophageal cancer	2.62e-05	9.74e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	2.58e-05	9.61e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ALOX15—esophageal cancer	2.57e-05	9.55e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.55e-05	9.48e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—HIF1A—esophageal cancer	2.55e-05	9.47e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—HIF1A—esophageal cancer	2.53e-05	9.43e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—KDR—esophageal cancer	2.52e-05	9.39e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—CYP1B1—esophageal cancer	2.52e-05	9.36e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—NOS3—esophageal cancer	2.5e-05	9.29e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.46e-05	9.14e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GSTO1—esophageal cancer	2.45e-05	9.11e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—TPI1—esophageal cancer	2.45e-05	9.11e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	2.45e-05	9.1e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—KDR—esophageal cancer	2.44e-05	9.06e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	2.43e-05	9.04e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—HIF1A—esophageal cancer	2.42e-05	9.02e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—KDR—esophageal cancer	2.42e-05	9.01e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling by GPCR—PIK3CA—esophageal cancer	2.38e-05	8.85e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—NOTCH1—esophageal cancer	2.38e-05	8.84e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—CYP19A1—esophageal cancer	2.37e-05	8.8e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Hemostasis—TP53—esophageal cancer	2.35e-05	8.74e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.35e-05	8.74e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—ERBB2—esophageal cancer	2.34e-05	8.69e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.32e-05	8.64e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—KDR—esophageal cancer	2.32e-05	8.63e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	2.31e-05	8.61e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.31e-05	8.59e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—CYP1B1—esophageal cancer	2.29e-05	8.54e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—NOTCH1—esophageal cancer	2.29e-05	8.54e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—NOTCH1—esophageal cancer	2.28e-05	8.49e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.26e-05	8.41e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.24e-05	8.34e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—HIF1A—esophageal cancer	2.24e-05	8.32e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—HIF1A—esophageal cancer	2.2e-05	8.19e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—HIF1A—esophageal cancer	2.19e-05	8.17e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	2.18e-05	8.13e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	2.18e-05	8.1e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—HMOX1—esophageal cancer	2.16e-05	8.03e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	2.16e-05	8.03e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—CREBBP—esophageal cancer	2.15e-05	8.02e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	2.15e-05	8.01e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—KDR—esophageal cancer	2.14e-05	7.96e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GNG7—esophageal cancer	2.13e-05	7.93e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.12e-05	7.88e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling by GPCR—EGFR—esophageal cancer	2.12e-05	7.88e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—HMOX1—esophageal cancer	2.11e-05	7.84e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—KDR—esophageal cancer	2.1e-05	7.83e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—KDR—esophageal cancer	2.1e-05	7.81e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CREBBP—esophageal cancer	2.08e-05	7.74e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—ABCB1—esophageal cancer	2.07e-05	7.71e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CREBBP—esophageal cancer	2.07e-05	7.7e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—CCND1—esophageal cancer	2.06e-05	7.68e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—KDR—esophageal cancer	2.06e-05	7.66e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling by GPCR—EGFR—esophageal cancer	2.04e-05	7.6e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling by GPCR—EGFR—esophageal cancer	2.03e-05	7.57e-05	CbGpPWpGaD
Trimipramine—ADRA2B—GPCR downstream signaling—PIK3CA—esophageal cancer	2.02e-05	7.53e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—NOTCH1—esophageal cancer	2.01e-05	7.49e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	2e-05	7.45e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ALDH2—esophageal cancer	2e-05	7.43e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—CDKN1A—esophageal cancer	2e-05	7.43e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.99e-05	7.39e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—NOTCH1—esophageal cancer	1.98e-05	7.37e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	1.98e-05	7.37e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—NOTCH1—esophageal cancer	1.98e-05	7.36e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.97e-05	7.33e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—CREBBP—esophageal cancer	1.95e-05	7.27e-05	CbGpPWpGaD
Trimipramine—HTR1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.95e-05	7.27e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	1.95e-05	7.24e-05	CbGpPWpGaD
Trimipramine—HTR2C—GPCR downstream signaling—PIK3CA—esophageal cancer	1.94e-05	7.23e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	1.94e-05	7.22e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.93e-05	7.19e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—NOS3—esophageal cancer	1.93e-05	7.18e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—KDR—esophageal cancer	1.91e-05	7.12e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.91e-05	7.09e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.9e-05	7.07e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—EP300—esophageal cancer	1.9e-05	7.07e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.89e-05	7.03e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.88e-05	6.99e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—NOS3—esophageal cancer	1.86e-05	6.93e-05	CbGpPWpGaD
Trimipramine—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	1.86e-05	6.92e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—NOS3—esophageal cancer	1.85e-05	6.89e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling by GPCR—PIK3CA—esophageal cancer	1.84e-05	6.84e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CREBBP—esophageal cancer	1.83e-05	6.79e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—ERBB2—esophageal cancer	1.8e-05	6.71e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	1.8e-05	6.71e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CREBBP—esophageal cancer	1.8e-05	6.69e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—EGFR—esophageal cancer	1.79e-05	6.68e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CREBBP—esophageal cancer	1.79e-05	6.67e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.78e-05	6.62e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ENO1—esophageal cancer	1.78e-05	6.62e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.77e-05	6.6e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	1.77e-05	6.6e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—EGFR—esophageal cancer	1.77e-05	6.57e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling by GPCR—PIK3CA—esophageal cancer	1.76e-05	6.57e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—EGFR—esophageal cancer	1.76e-05	6.56e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	1.76e-05	6.55e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PSME2—esophageal cancer	1.75e-05	6.53e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PSME1—esophageal cancer	1.75e-05	6.53e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—NOS3—esophageal cancer	1.75e-05	6.51e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—ERBB2—esophageal cancer	1.74e-05	6.48e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—ERBB2—esophageal cancer	1.73e-05	6.45e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	1.73e-05	6.43e-05	CbGpPWpGaD
Trimipramine—DRD2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.71e-05	6.38e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	1.69e-05	6.29e-05	CbGpPWpGaD
Trimipramine—HTR2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.69e-05	6.28e-05	CbGpPWpGaD
Trimipramine—HRH1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.68e-05	6.27e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	1.66e-05	6.17e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—MYC—esophageal cancer	1.65e-05	6.16e-05	CbGpPWpGaD
Trimipramine—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.65e-05	6.15e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—NOS3—esophageal cancer	1.63e-05	6.08e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	1.63e-05	6.08e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—EGFR—esophageal cancer	1.62e-05	6.02e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—NOS3—esophageal cancer	1.61e-05	5.99e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	1.61e-05	5.98e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—NOS3—esophageal cancer	1.61e-05	5.97e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PTGS2—esophageal cancer	1.6e-05	5.96e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—CCND1—esophageal cancer	1.59e-05	5.93e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	1.58e-05	5.86e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.57e-05	5.83e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—PIK3CA—esophageal cancer	1.56e-05	5.8e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—CDKN1A—esophageal cancer	1.54e-05	5.74e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CCND1—esophageal cancer	1.54e-05	5.73e-05	CbGpPWpGaD
Trimipramine—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.54e-05	5.71e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.53e-05	5.7e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CCND1—esophageal cancer	1.53e-05	5.7e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—ERBB2—esophageal cancer	1.53e-05	5.69e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—PIK3CA—esophageal cancer	1.53e-05	5.69e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.51e-05	5.63e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—ERBB2—esophageal cancer	1.5e-05	5.6e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—ERBB2—esophageal cancer	1.5e-05	5.59e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	1.5e-05	5.58e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CDKN1A—esophageal cancer	1.49e-05	5.54e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CDKN1A—esophageal cancer	1.48e-05	5.51e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	1.47e-05	5.48e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—EP300—esophageal cancer	1.47e-05	5.46e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	1.47e-05	5.45e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	1.46e-05	5.45e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.43e-05	5.32e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.42e-05	5.29e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	1.42e-05	5.28e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—EP300—esophageal cancer	1.42e-05	5.27e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—EP300—esophageal cancer	1.41e-05	5.24e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—PIK3CA—esophageal cancer	1.4e-05	5.23e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	1.39e-05	5.19e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—CREBBP—esophageal cancer	1.38e-05	5.15e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	1.37e-05	5.09e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—TP53—esophageal cancer	1.36e-05	5.06e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—CREBBP—esophageal cancer	1.35e-05	5.03e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CCND1—esophageal cancer	1.35e-05	5.03e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—EP300—esophageal cancer	1.35e-05	5.02e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—EP300—esophageal cancer	1.33e-05	4.95e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CCND1—esophageal cancer	1.33e-05	4.95e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CCND1—esophageal cancer	1.33e-05	4.94e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CDKN1A—esophageal cancer	1.31e-05	4.86e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	1.3e-05	4.84e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.3e-05	4.83e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CDKN1A—esophageal cancer	1.29e-05	4.79e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CDKN1A—esophageal cancer	1.28e-05	4.78e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MYC—esophageal cancer	1.28e-05	4.76e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.27e-05	4.74e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—CREBBP—esophageal cancer	1.26e-05	4.7e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	1.26e-05	4.69e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—EGFR—esophageal cancer	1.25e-05	4.65e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.25e-05	4.64e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—EP300—esophageal cancer	1.24e-05	4.63e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—NOS3—esophageal cancer	1.24e-05	4.61e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MYC—esophageal cancer	1.23e-05	4.59e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MYC—esophageal cancer	1.23e-05	4.57e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—EP300—esophageal cancer	1.22e-05	4.55e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—EP300—esophageal cancer	1.22e-05	4.54e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—NOS3—esophageal cancer	1.21e-05	4.5e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	1.21e-05	4.5e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—EGFR—esophageal cancer	1.21e-05	4.49e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—EGFR—esophageal cancer	1.2e-05	4.47e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—EP300—esophageal cancer	1.2e-05	4.46e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MYC—esophageal cancer	1.18e-05	4.37e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	1.17e-05	4.35e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	1.15e-05	4.28e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—NOS3—esophageal cancer	1.14e-05	4.24e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PTGS2—esophageal cancer	1.13e-05	4.22e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—NOS3—esophageal cancer	1.13e-05	4.21e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—EP300—esophageal cancer	1.11e-05	4.14e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PTGS2—esophageal cancer	1.11e-05	4.12e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—PIK3CA—esophageal cancer	1.09e-05	4.04e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MYC—esophageal cancer	1.08e-05	4.03e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MYC—esophageal cancer	1.07e-05	3.97e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MYC—esophageal cancer	1.06e-05	3.96e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—EGFR—esophageal cancer	1.06e-05	3.94e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—TP53—esophageal cancer	1.05e-05	3.91e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—PIK3CA—esophageal cancer	1.05e-05	3.9e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MYC—esophageal cancer	1.04e-05	3.89e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.04e-05	3.88e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—EGFR—esophageal cancer	1.04e-05	3.88e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—PIK3CA—esophageal cancer	1.04e-05	3.88e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—EGFR—esophageal cancer	1.04e-05	3.87e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PTGS2—esophageal cancer	1.03e-05	3.85e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	1.02e-05	3.8e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—TP53—esophageal cancer	1.01e-05	3.77e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—TP53—esophageal cancer	1.01e-05	3.75e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	9.98e-06	3.71e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PIK3CA—esophageal cancer	9.85e-06	3.66e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MYC—esophageal cancer	9.7e-06	3.61e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—TP53—esophageal cancer	9.65e-06	3.59e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	9.49e-06	3.53e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—EP300—esophageal cancer	9.43e-06	3.51e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—EP300—esophageal cancer	9.21e-06	3.43e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—PIK3CA—esophageal cancer	9.2e-06	3.42e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PIK3CA—esophageal cancer	9.05e-06	3.37e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PIK3CA—esophageal cancer	9.03e-06	3.36e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—TP53—esophageal cancer	8.9e-06	3.31e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	8.86e-06	3.3e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—TP53—esophageal cancer	8.76e-06	3.26e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—TP53—esophageal cancer	8.74e-06	3.25e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—EP300—esophageal cancer	8.68e-06	3.23e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—EP300—esophageal cancer	8.6e-06	3.2e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—TP53—esophageal cancer	8.57e-06	3.19e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CREBBP—esophageal cancer	8.33e-06	3.1e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	8.24e-06	3.06e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—TP53—esophageal cancer	7.97e-06	2.96e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—NOS3—esophageal cancer	7.46e-06	2.77e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PIK3CA—esophageal cancer	6.98e-06	2.6e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PTGS2—esophageal cancer	6.82e-06	2.54e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PIK3CA—esophageal cancer	6.81e-06	2.53e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	6.42e-06	2.39e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	6.36e-06	2.37e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—EP300—esophageal cancer	5.67e-06	2.11e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	4.2e-06	1.56e-05	CbGpPWpGaD
